HeimPHS • FRA
add
Photocure ASA
Við síðustu lokun
4,20 €
Dagbil
4,16 € - 4,16 €
Árabil
4,01 € - 6,13 €
V/H-hlutf.
-
A/V-hlutfall
-
Viðskiptafréttir
CNBC
fyrir 1 klukkustund
Stock futures are little changed as earnings season gains steam: Live
updates
0,80%
0,18%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (NOK) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 145,45 m. | 0,78% |
Rekstrarkostnaður | 117,16 m. | -2,85% |
Nettótekjur | 12,33 m. | 186,06% |
Hagnaðarhlutfall | 8,48 | 183,61% |
Hagnaður á hvern hlut | 0,45 | 181,25% |
EBITDA | 27,85 m. | 19,06% |
Virkt skatthlutfall | 23,70% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (NOK) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 266,99 m. | 3,11% |
Heildareignir | 713,58 m. | 0,99% |
Heildarskuldir | 213,92 m. | -10,51% |
Eigið fé alls | 499,66 m. | — |
Útistandandi hlutabréf | 27,11 m. | — |
Eiginfjárgengi | 0,23 | — |
Arðsemi eigna | 7,23% | — |
Ávöxtun eigin fjár | 10,18% | — |
Peningaflæði
Breyting á handbæru fé
| (NOK) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 12,33 m. | 186,06% |
Handbært fé frá rekstri | 19,52 m. | -32,96% |
Reiðufé frá fjárfestingum | 472,00 þ. | 265,89% |
Reiðufé frá fjármögnun | -11,27 m. | 31,02% |
Breyting á handbæru fé | 8,72 m. | -32,43% |
Frjálst peningaflæði | 5,25 m. | -65,93% |
Um
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Stofnsett
1993
Vefsvæði
Starfsfólk
102
